A new class of therapies to address cancer’s lethal ability to evolve resistance to treatment

ApoGen Biotechnologies, Inc. focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutations. ApoGen built upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance.

Daniel A. Harki, PhD
Reuben S. Harris, PhD
John T. Santini, Jr, Ph.D.